Tatva Chintan Pharma Chem IPO - Strengths, Strategies, Risks: Anand Rathi
An employee mixes a solution at a research laboratory. (Photographer: Dario Pignatelli/Bloomberg)

Tatva Chintan Pharma Chem IPO - Strengths, Strategies, Risks: Anand Rathi


BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Anand Rathi Research's IPO Report

Tatva Chintan Pharma Chem Ltd. is a specialty chemicals manufacturing company engaged in the manufacture of a diverse portfolio of structure directing agent, phase transfer catalyst, electrolyte salts for super capacitor batteries and pharmaceutical and agrochemical intermediates and other specialty chemicals.

The company is the largest and only commercial manufacturer of SDAs for zeolites in India. It also enjoys the second largest position globally.

Tatva Chintan Pharma Chem operates through two manufacturing facilities situated at Ankleshwar and Dahej in Gujarat, both of which are strategically located very close to the Hazira port. These manufacturing facilities have an annual installed reactor capacity of 280 KL and 17 Assembly Lines.

Click on the attachment to read the full IPO report:

Anand Rathi IPO Note Tatva Chintan Pharma Chem Ltd..pdf


This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.